^
    20h
    Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    12d
    LOXO-RAS-20001: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (clinicaltrials.gov)
    P1/2, N=540, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed • olomorasib (LY3537982)
    13d
    A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=12, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Mar 2026 | Trial primary completion date: Apr 2026 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    olomorasib (LY3537982)
    13d
    A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants (clinicaltrials.gov)
    P1, N=120, Completed, Eli Lilly and Company | Recruiting --> Completed
    Trial completion
    |
    olomorasib (LY3537982)
    23d
    A Study of Olomorasib (LY3537982) in Healthy Participants (clinicaltrials.gov)
    P1, N=15, Completed, Eli Lilly and Company | Recruiting --> Completed
    Trial completion
    |
    olomorasib (LY3537982)
    1m
    Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. (PubMed, Nat Commun)
    These findings suggest that olomorasib could be effective for patients with KRASG12C mutant cancers either as monotherapy or in combination with immunotherapy. Olomorasib monotherapy and combination treatments are currently being investigated clinically.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    olomorasib (LY3537982)
    1m
    SUNRAY-01: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1264, Recruiting, Eli Lilly and Company | N=537 --> 1264
    Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • olomorasib (LY3537982)
    2ms
    A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function (clinicaltrials.gov)
    P1, N=32, Completed, Eli Lilly and Company | Recruiting --> Completed
    Trial completion
    |
    olomorasib (LY3537982)
    2ms
    SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. (PubMed, Future Oncol)
    www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    3ms
    A Study of Olomorasib (LY3537982) in Healthy Participants (clinicaltrials.gov)
    P1, N=15, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olomorasib (LY3537982)
    3ms
    KaRAnaSa: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2028 --> Apr 2029
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Rybrevant (amivantamab-vmjw) • olomorasib (LY3537982)
    3ms
    Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. (PubMed, Nat Commun)
    Intracranial responses were observed in patients with untreated, active brain metastases. This may support the potential of next-generation KRAS G12C inhibitors to overcome limitations of earlier agents and justify further investigation of combination therapy.
    P1 data • Journal • Pan tumor • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    olomorasib (LY3537982)